MDMA administration decreases serotonin but not N-acetylaspartate in the rat brain

NeuroToxicology

Volumn 31, Issue 6, 2010, Pages 654-661

  Perrine, Shane A ^a   Ghoddoussi, Farhad ^a   Michaels, Mark S ^a   Hyde, Elisabeth M ^a   Kuhn, Donald M ^a   Galloway, Matthew P ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Glutamate; Hippocampus; Magnetic resonance spectroscopy; MDMA; Neurotoxicity; Rat

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 AMINOBUTYRIC ACID; GLUTAMIC ACID; INOSITOL; MONOAMINE; N ACETYLASPARTIC ACID; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIPPOCAMPUS; MALE; NEUROTOXICITY; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RAT;

ANIMALS; ASPARTIC ACID; BRAIN; BRAIN CHEMISTRY; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; SEROTONIN ANTAGONISTS;

ANIMALIA; RATTUS;

EID: 78049464449     PISSN: 0161813X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuro.2010.08.005     Document Type: Article

References (77)

1. Aguirre N., Barrionuevo M., Ramirez M.J., Del Rio J., Lasheras B. Alpha-lipoic acid prevents 3,4-methylenedioxy-methamphetamine (MDMA)-induced neurotoxicity. Neuroreport 1999, 10:3675-3680.
2. Ball K.T., Wellman C.L., Fortenberry E., Rebec G.V. Sensitizing regimens of (+/-)3,4-methylenedioxymethamphetamine (ecstasy) elicit enduring and differential structural alterations in the brain motive circuit of the rat. Neuroscience 2009, 160:264-274.
3. Battaglia G., Yeh S.Y., O'Hearn E., Molliver M.E., Kuhar M.J., De Souza E.B. 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. J Pharmacol Exp Ther. 1987, 242:911-916.
4. Bianchi M.C., Sgandurra G., Tosetti M., Battini R., Cioni G. Brain magnetic resonance in the diagnostic evaluation of mitochondrial encephalopathies. Biosci Rep 2007, 27:69-85.
5. Bitsch A., Bruhn H., Vougioukas V., Stringaris A., Lassmann H., Frahm J., et al. Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. Am J Neuroradiol 1999, 20:1619-1627.
6. Buchert R., Thomasius R., Wilke F., Petersen K., Nebeling B., Obrocki J., et al. A voxel-based PET investigation of the long-term effects of " Ecstasy" consumption on brain serotonin transporters. Am J Psychiatry 2004, 161:1181-1189.
7. Camicioli R.M., Hanstock C.C., Bouchard T.P., Gee M., Fisher N.J., Martin W.R. Magnetic resonance spectroscopic evidence for presupplementary motor area neuronal dysfunction in Parkinson's disease. Mov Disord 2007, 22:382-386.
8. Cavassila S., Deval S., Huegen C., van Ormondt D., Graveron-Demilly D. Cramer-Rao bounds: an evaluation tool for quantitation. NMR Biomed 2001, 14:278-283.
9. Chang L., Ernst T., Grob C.S., Poland R.E. Cerebral (1)H MRS alterations in recreational 3,4-methylenedioxymethamphetamine (MDMA, " ecstasy") users. J Magn Reson Imaging 1999, 10:521-526.
10. Colado M.I., O'Shea E., Esteban B., Green A.R. Studies on the neuroprotective effect of the enantiomers of AR-A008055, a compound structurally related to clomethiazole, on MDMA (" ecstasy")-induced neurodegeneration in rat brain. Psychopharmacology (Berl) 2001, 157:82-88.
11. Commins D.L., Vosmer G., Virus R.M., Woolverton W.L., Schuster C.R., Seiden L.S. Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. J Pharmacol Exp Ther 1987, 241:338-345.
12. Cowan R.L. Neuroimaging research in human MDMA users: a review. Psychopharmacology (Berl) 2007, 189:539-556.
13. Cowan R.L., Bolo N.R., Dietrich M., Haga E., Lukas S.E., Renshaw P.F. Occipital cortical proton MRS at 4 Tesla in human moderate MDMA polydrug users. Psychiatry Res 2007, 155:179-188.
14. Cowan R.L., Joers J.M., Dietrich M.S. N-acetylaspartate (NAA) correlates inversely with cannabis use in a frontal language processing region of neocortex in MDMA (Ecstasy) polydrug users: a 3T magnetic resonance spectroscopy study. Pharmacol Biochem Behav 2009, 92:105-110.
15. Cowan R.L., Roberts D.M., Joers J.M. Neuroimaging in human MDMA (Ecstasy) users. Ann N Y Acad Sci 2008, 1139:291-298.
16. Daumann J., Fischermann T., Pilatus U., Thron A., Moeller-Hartmann W., Gouzoulis-Mayfrank E. Proton magnetic resonance spectroscopy in ecstasy (MDMA) users. Neurosci Lett 2004, 362:113-116.
17. De La Garza R., Fabrizio K.R., Gupta A. Relevance of rodent models of intravenous MDMA self-administration to human MDMA consumption patterns. Psychopharmacology (Berl) 2007, 189:425-434.
18. de Win M.M., Jager G., Booij J., Reneman L., Schilt T., Lavini C., et al. Sustained effects of ecstasy on the human brain: a prospective neuroimaging study in novel users. Brain 2008, 131:2936-2945.
19. de Win M.M., Reneman L., Jager G., Vlieger E.J., Olabarriaga S.D., Lavini C., et al. A prospective cohort study on sustained effects of low-dose ecstasy use on the brain in new ecstasy users. Neuropsychopharmacology 2007, 32:458-470.
20. Duc C.O., Trabesinger A.H., Weber O.M., Meier D., Walder M., Wieser H.G., et al. Quantitative 1H MRS in the evaluation of mesial temporal lobe epilepsy in vivo. Magn Reson Imaging 1998, 16:969-979.
21. Fantegrossi W.E., Ciullo J.R., Wakabayashi K.T., De La Garza R., Traynor J.R., et al. A comparison of the physiological, behavioral, neurochemical and microglial effects of methamphetamine and 3,4-methylenedioxymethamphetamine in the mouse. Neuroscience 2008, 151:533-543.
22. Fowler J.S., Volkow N.D., Kassed C.A., Chang L. Imaging the addicted human brain. Sci Pract Perspect 2007, 3:4-16.
23. Gao H., Xiang Y., Sun N., Zhu H., Wang Y., Liu M., et al. Metabolic changes in rat prefrontal cortex and hippocampus induced by chronic morphine treatment studied ex vivo by high resolution 1H NMR spectroscopy. Neurochem Int 2007, 50:386-394.
24. Ghoddoussi F., Galloway M.P., Jambekar A., Bame M., Needleman R., Brusilow W.S. Methionine sulfoximine, an inhibitor of glutamine synthetase, lowers brain glutamine and glutamate in a mouse model of ALS. J Neurol Sci 2010, 290:41-47.
25. Green A.R., Mechan A.O., Elliott J.M., O'Shea E., Colado M.I. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, " ecstasy"). Pharmacol Rev 2003, 55:463-508.
26. Gudelsky G.A., Yamamoto B.K. Actions of 3,4-methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons. Pharmacol Biochem Behav 2008, 90:198-207.
27. Guillot C.R., Berman M.E. MDMA (Ecstasy) use and psychiatric problems. Psychopharmacology (Berl) 2007, 189:575-576.
28. Guimaraes A.R., Schwartz P., Prakash M.R., Carr C.A., Berger U.V., Jenkins B.G., et al. Quantitative in vivo 1H nuclear magnetic resonance spectroscopic imaging of neuronal loss in rat brain. Neuroscience 1995, 69:1095-1101.
29. Hajek M., Dezortova M., Komarek V. 1H MR spectroscopy in patients with mesial temporal epilepsy. Magma 1998, 7:95-114.
30. Kindlundh-Hogberg A.M., Blomqvist A., Malki R., Schioth H.B. Extensive neuroadaptive changes in cortical gene-transcript expressions of the glutamate system in response to repeated intermittent MDMA administration in adolescent rats. BMC Neurosci 2008, 9:39.
31. Koch S., Galloway M.P. MDMA induced dopamine release in vivo: role of endogenous serotonin. J Neural Transm 1997, 104:135-146.
32. Kuhn D.M., Geddes T.J. Molecular footprints of neurotoxic amphetamine action. Ann N Y Acad Sci 2000, 914:92-103.
33. Lambe E.K., Aghajanian G.K. The role of Kv1.2-containing potassium channels in serotonin-induced glutamate release from thalamocortical terminals in rat frontal cortex. J Neurosci 2001, 21:9955-9963.
34. Lambe E.K., Aghajanian G.K. Prefrontal cortical network activity: Opposite effects of psychedelic hallucinogens and D1/D5 dopamine receptor activation. Neuroscience 2007, 145:900-910.
35. Lambe E.K., Goldman-Rakic P.S., Aghajanian G.K. Serotonin induces EPSCs preferentially in layer V pyramidal neurons of the frontal cortex in the rat. Cereb Cortex 2000, 10:974-980.
36. Maier M., Ron M.A., Barker G.J., Tofts P.S. Proton magnetic resonance spectroscopy: an in vivo method of estimating hippocampal neuronal depletion in schizophrenia. Psychol Med 1995, 25:1201-1209.
37. McCann U.D., Slate S.O., Ricaurte G.A. Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy'). Drug Saf 1996, 15:107-115.
38. McCann U.D., Szabo Z., Scheffel U., Dannals R.F., Ricaurte G.A. Positron emission tomographic evidence of toxic effect of MDMA (" Ecstasy") on brain serotonin neurons in human beings. Lancet 1998, 352:1433-1437.
39. McCann U.D., Szabo Z., Seckin E., Rosenblatt P., Mathews W.B., Ravert H.T., et al. Quantitative PET studies of the serotonin transporter in MDMA users and controls using [11C]McN5652 and [11C]DASB. Neuropsychopharmacology 2005, 30:1741-1750.
40. Mendes-Ribeiro J.A., Soares R., Simoes-Ribeiro F., Guimaraes M.L. Reduction in temporal N-acetylaspartate and creatine (or choline) ratio in temporal lobe epilepsy: does this 1H-magnetic resonance spectroscopy finding mean poor seizure control?. J Neurol Neurosurg Psychiatry 1998, 65:518-522.
41. Meyer J.S., Brevard M.E., Piper B.J., Ali S.F., Ferris C.F. Neural effects of MDMA as determined by functional magnetic resonance imaging and magnetic resonance spectroscopy in awake marmoset monkeys. Ann N Y Acad Sci 2006, 1074:365-376.
42. Montoya A.G., Sorrentino R., Lukas S.E., Price B.H. Long-term neuropsychiatric consequences of " ecstasy" (MDMA): a review. Harv Rev Psychiatry 2002, 10:212-220.
43. Moore G.J., Galloway M.P. Magnetic resonance spectroscopy: neurochemistry and treatment effects in affective disorders. Psychopharmacol Bull 2002, 36:5-23.
44. Morgan M.J., Impallomeni L.C., Pirona A., Rogers R.D. Elevated impulsivity and impaired decision-making in abstinent Ecstasy (MDMA) users compared to polydrug and drug-naive controls. Neuropsychopharmacology 2006, 31:1562-1573.
45. O'Hearn E., Battaglia G., De Souza E.B., Kuhar M.J., Molliver M.E. Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J Neurosci 1988, 8:2788-2803.
46. O'Leary-Moore S.K., Galloway M.P., McMechan A.P., Hannigan J.H., Bowen S.E. Region-dependent alterations in glutamate and GABA measured by high-resolution magnetic resonance spectroscopy following acute binge inhalation of toluene in juvenile rats. Neurotoxicol Teratol 2007, 29(4):466-475.
47. O'Leary-Moore S.K., McMechan A.P., Galloway M.P., Hannigan J.H. Neonatal alcohol-induced region-dependent changes in rat brain neurochemistry measured by high-resolution magnetic resonance spectroscopy. Alcohol Clin Exp Res 2008, 32:1697-1707.
48. Obergriesser T., Ende G., Braus D.F., Henn F.A. Hippocampal 1H-MRSI in ecstasy users. Eur Arch Psychiatry Clin Neurosci 2001, 251:114-116.
49. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 2006, Academic Press, London. 6 ed.
50. Perrine S.A., Michaels M.S., Ghoddoussi F., Hyde E.M., Tancer M.E., Galloway M.P. Cardiac effects of MDMA on the metabolic profile determined with (1)H-magnetic resonance spectroscopy in the rat. NMR Biomed 2008.
51. Provencher S.W. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993, 30:672-679.
52. Reneman L., Booij J., Habraken J.B., De Bruin K., Hatzidimitriou G., Den Heeten G.J., et al. Validity of [123I]beta-CIT SPECT in detecting MDMA-induced serotonergic neurotoxicity. Synapse 2002, 46:199-205.
53. Reneman L., Endert E., de Bruin K., Lavalaye J., Feenstra M.G., de Wolff F.A., et al. The acute and chronic effects of MDMA (" ecstasy") on cortical 5-HT2A receptors in rat and human brain. Neuropsychopharmacology 2002, 26:387-396.
54. Reneman L., Majoie C.B., Flick H., den Heeten G.J. Reduced N-acetylaspartate levels in the frontal cortex of 3,4-methylenedioxymethamphetamine (Ecstasy) users: preliminary results. Am J Neuroradiol 2002, 23:231-237.
55. Reneman L., Majoie C.B., Schmand B., van den Brink W., den Heeten G.J. Prefrontal N-acetylaspartate is strongly associated with memory performance in (abstinent) ecstasy users: preliminary report. Biol Psychiatry 2001, 50:550-554.
56. Ricaurte G.A., DeLanney L.E., Irwin I., Langston J.W. Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration. Brain Res 1988, 446:165-168.
57. Ricaurte G.A., McCann U.D. Experimental studies on 3,4-methylenedioxymethamphetamine (MDA, " ecstasy") and its potential to damage brain serotonin neurons. Neurotox Res 2001, 3:85-99.
58. Rothman D.L., Behar K.L., Hyder F., Shulman R.G. In vivo NMR studies of the glutamate neurotransmitter flux and neuroenergetics: implications for brain function. Annu Rev Physiol 2003, 65:401-427.
59. Rumpel H., Lim W.E., Chang H.M., Chan L.L., Ho G.L., Wong M.C., et al. Is myo-inositol a measure of glial swelling after stroke? A magnetic resonance study. J Magn Reson Imaging 2003, 17:11-19.
60. Sanacora G., Mason G.F., Krystal J.H. Impairment of GABAergic transmission in depression: new insights from neuroimaging studies. Crit Rev Neurobiol 2000, 14:23-45.
61. Sanacora G., Saricicek A. GABAergic contributions to the pathophysiology of depression and the mechanism of antidepressant action. CNS Neurol Disord Drug Targets 2007, 6:127-140.
62. Saneto R.P., Friedman S.D., Shaw D.W. Neuroimaging of mitochondrial disease. Mitochondrion 2008, 8:396-413.
63. Scheffel U., Szabo Z., Mathews W.B., Finley P.A., Dannals R.F., Ravert H.T., et al. In vivo detection of short- and long-term MDMA neurotoxicity-a positron emission tomography study in the living baboon brain. Synapse 1998, 29:183-192.
64. Schmued L.C. Demonstration and localization of neuronal degeneration in the rat forebrain following a single exposure to MDMA. Brain Res 2003, 974:127-133.
65. Sesack S.R., Grace A.A. Cortico-Basal Ganglia reward network: microcircuitry. Neuropsychopharmacology 2010, 35:27-47.
66. Sharma R., Venkatasubramanian P.N., Barany M., Davis J.M. Proton magnetic resonance spectroscopy of the brain in schizophrenic and affective patients. Schizophr Res 1992, 8:43-49.
67. Shulman R.G., Blamire A.M., Rothman D.L., McCarthy G. Nuclear magnetic resonance imaging and spectroscopy of human brain function. Proc Natl Acad Sci U S A 1993, 90:3127-3133.
68. Simmons M.L., Frondoza C.G., Coyle J.T. Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 1991, 45:37-45.
69. Slikker W., Ali S.F., Scallet A.C., Frith C.H., Newport G.D., Bailey J.R. Neurochemical and neurohistological alterations in the rat and monkey produced by orally administered methylenedioxymethamphetamine (MDMA). Toxicol Appl Pharmacol 1988, 94:448-457.
70. Strauss I., Williamson J.M., Bertram E.H., Lothman E.W., Fernandez E.J. Histological and 1H magnetic resonance spectroscopic imaging analysis of quinolinic acid-induced damage to the rat striatum. Magn Reson Med 1997, 37:24-33.
71. Thomas D.M., Dowgiert J., Geddes T.J., Francescutti-Verbeem D., Liu X., Kuhn D.M. Microglial activation is a pharmacologically specific marker for the neurotoxic amphetamines. Neurosci Lett 2004, 367:349-354.
72. Thomasius R., Petersen K.U., Zapletalova P., Wartberg L., Zeichner D., Schmoldt A. Mental disorders in current and former heavy ecstasy (MDMA) users. Addiction 2005, 100:1310-1319.
73. Thomasius R., Zapletalova P., Petersen K., Buchert R., Andresen B., Wartberg L., et al. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective. J Psychopharmacol 2006, 20:211-225.
74. Tkac I., Oz G., Adriany G., Ugurbil K., Gruetter R. In vivo 1H NMR spectroscopy of the human brain at high magnetic fields: metabolite quantification at 4T vs 7T. Magn Reson Med 2009, 62:868-879.
75. Urenjak J., Williams S.R., Gadian D.G., Noble M. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci 1993, 13:981-989.
76. Wang X., Baumann M.H., Xu H., Rothman R.B. 3,4-Methylenedioxymethamphetamine (MDMA) administration to rats decreases brain tissue serotonin but not serotonin transporter protein and glial fibrillary acidic protein. Synapse 2004, 53:240-248.
77. Yamamoto B.K., Raudensky J. The role of oxidative stress, metabolic compromise, and inflammation in neuronal injury produced by amphetamine-related drugs of abuse. J Neuroimmune Pharmacol 2008, 3:203-217.